GT Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by GT Biopharma, Inc. (GTBP) on May 20, 2026. The Company is a Delaware corporation listed on The Nasdaq Stock Market LLC. As of July 1, 2024, the Company operates as a fully remote entity without a principal executive office.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes and Listing Status
On May 20, 2026, the Company received notification from Nasdaq granting an additional 180-day compliance period to regain compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Requirement of $1.00 per share. The new deadline to demonstrate compliance is November 16, 2026. This extension follows an initial notification on November 20, 2025, regarding the stock price falling below $1.00 for 30 consecutive business days. The Company remains eligible for this extension as it meets all other initial listing requirements, including the market value of publicly held shares.
Outlook, Risks, and Management Commentary
Management intends to monitor the closing bid price and assess available options to regain compliance. The filing explicitly states there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price requirement or maintain compliance with other applicable Nasdaq listing rules. Failure to comply by the November 16, 2026 deadline could result in delisting.
Investor Verification Checklist
- Verify the current closing bid price of GTBP common stock relative to the $1.00 threshold.
- Monitor the Company's progress toward maintaining a $1.00 closing bid price for 10 consecutive business days before November 16, 2026.
- Review subsequent filings for any announcements regarding reverse stock splits or other capital structure changes intended to address the bid price deficiency.
- Confirm the Company's continued compliance with other Nasdaq listing standards, such as the market value of publicly held shares.